Zomedica Corp. (NYSEAMERICAN:ZOM - Get Free Report) shares shot up 1.6% during trading on Friday . The stock traded as high as $0.12 and last traded at $0.12. 3,811,875 shares changed hands during mid-day trading, a decline of 47% from the average session volume of 7,158,155 shares. The stock had previously closed at $0.12.
Analyst Ratings Changes
Separately, Noble Financial raised shares of Zomedica to a "strong-buy" rating in a research note on Monday, November 11th.
Get Our Latest Report on Zomedica
Zomedica Trading Up 0.2 %
The firm has a market capitalization of $118.87 million, a P/E ratio of -2.02 and a beta of 1.03.
Zomedica (NYSEAMERICAN:ZOM - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.01) EPS for the quarter. Zomedica had a negative return on equity of 12.47% and a negative net margin of 232.88%. The company had revenue of $7.00 million during the quarter. On average, equities analysts predict that Zomedica Corp. will post -0.05 EPS for the current year.
Institutional Trading of Zomedica
An institutional investor recently raised its position in Zomedica stock. Geode Capital Management LLC increased its position in shares of Zomedica Corp. (NYSEAMERICAN:ZOM - Free Report) by 3.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,929,716 shares of the company's stock after acquiring an additional 321,395 shares during the quarter. Geode Capital Management LLC owned approximately 1.01% of Zomedica worth $1,363,000 as of its most recent filing with the SEC. 8.95% of the stock is currently owned by hedge funds and other institutional investors.
Zomedica Company Profile
(
Get Free Report)
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
Featured Stories
Before you consider Zomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zomedica wasn't on the list.
While Zomedica currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
